Dr. Robert L. Scott, M.D.
Cardiology (Cardiovascular Disease Physician)
5779 E Mayo Blvd
Phoenix, AZ 85054
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,324
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
AZ license 34503 -
Advanced Heart Failure and Transplant Cardiology Physician
AZ license 34503
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Phoenix, AZ
Medical groups
- Mayo Clinic Arizona (1,626 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,324
- Services billed
- 1,688
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 198 | 190 |
| Established patient office or other outpatient visit, 30-39 minutes | 163 | 138 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 143 | 143 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 58 |
| New patient office or other outpatient visit, 30-44 minutes | 58 | 58 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 37 |
| New patient office or other outpatient visit, 45-59 minutes | 34 | 34 |
| Insertion of tube in right heart chambers for measurement | 29 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 26 | 19 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 14 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Opsumit (macitentan) | 362 |
| Uptravi (selexipag) | 217 |
| Spironolactone Other prescribers in Phoenix, AZ | 200 |
| Entresto (sacubitril/valsartan) Other prescribers in Phoenix, AZ | 162 |
| Tacrolimus Other prescribers in Phoenix, AZ | 151 |
| Atorvastatin Calcium Other prescribers in Phoenix, AZ | 123 |
| Adempas (riociguat) | 113 |
| Metoprolol Succinate Other prescribers in Phoenix, AZ | 109 |
| Eliquis (apixaban) Other prescribers in Phoenix, AZ | 102 |
| Losartan Potassium Other prescribers in Phoenix, AZ | 88 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 23 payments worth $22,349 in total to this clinician.
| Actelion Pharmaceuticals US, Inc. | $22,328 |
|---|---|
| Inspire Medical Systems, Inc. | $20.94 |
| Compensation for services other than consulting (speaking, faculty) | $19,238 |
|---|---|
| Travel and Lodging | $2,325 |
| Food and Beverage | $786 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $8,100 |
| Actelion Pharmaceuticals US, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,725 |
| Actelion Pharmaceuticals US, Inc. Oct 27, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $4,050 |
| Actelion Pharmaceuticals US, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,363 |
| Actelion Pharmaceuticals US, Inc. Aug 11, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Lake Havasu City, AZ · in-kind | $2,314 |
| Actelion Pharmaceuticals US, Inc. Jul 22, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Lake Havasu City, AZ · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Aug 4, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Lake Havasu City, AZ · in-kind | $5.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,217 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Ma…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.